更新于：2024-05-16

Human immunoglobulin(Sinopharm Group Shanghai Blood Products)

人免疫球蛋白(PH4)(国药集团上海血液制品有限公司)

更新于：2024-05-16

概要

概要

基本信息

药物类型

免疫球蛋白

别名-

靶点-

作用机制

免疫调节剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

国药集团上海血液制品有限公司

在研机构

国药集团上海血液制品有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (1997-01-01)

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

关联

100 项与人免疫球蛋白(PH4)(国药集团上海血液制品有限公司) 相关的临床结果

登录后查看更多信息

100 项与人免疫球蛋白(PH4)(国药集团上海血液制品有限公司) 相关的转化医学

登录后查看更多信息

100 项与人免疫球蛋白(PH4)(国药集团上海血液制品有限公司) 相关的专利（医药）

登录后查看更多信息

项与人免疫球蛋白(PH4)(国药集团上海血液制品有限公司) 相关的文献（医药）

2024-03-01·Clinical Rheumatology

The effect of COVID-19 infection on patients with rheumatic diseases in China

Article

作者: Du, Mengru ; Xu, Xue ; Geng, Lingyu ; Zhao, Zhiling ; Liang, Jun ; Yan, Yunxia ; Chen, Haifeng ; Wang, Dandan ; Sun, Lingyun ; Lai, Peng

OBJECTIVESAt the end of 2022, the COVID-19 outbreak erupted in China, and BA.5.2 or BF.7 subtypes of Omicron novel variations were implicated in more than 90% of the cases. We created a real-world questionnaire survey to better understand how this new variant pandemic was affecting rheumatic patients in China.METHODSDuring the COVID-19 outbreak in China, the subjects of this study were rheumatic patients and non-rheumatic individuals (control group), who were matched for sex and age. Professional physicians carefully questioned the participants before administering a questionnaire as part of the study. This study focused on the general baseline characteristics, clinical symptoms and treatment after COVID-19 infection, and the target populations' awareness of COVID-19.RESULTSThe study included 1130 participants, of whom 572 were assigned to the rheumatic group and 558 to the control group. The percentage of vaccinated controls was significantly higher than that of rheumatic patients (90.1% vs. 62.8%, p < 0.001), while the rate of COVID-19 infection was not significantly different between the two groups (82.3% vs. 86.6%, p = 0.051). Patients with rheumatic disease experienced substantially more days of fever following infection (2.87 ± 3.42 vs. 2.18 ± 1.65, p = 0.002) compared to individuals in the control group. The rheumatic patients had a greater prevalence of cough (67.1% vs. 54.0%, p < 0.001), somnipathy (13.8% vs. 6.0%, p < 0.001), and conjunctivitis/ophthalmodynia (5.3% vs. 2.1%, p = 0.008), while dry throat/throat pain/weakness (49.9% vs. 59.4%, p = 0.003), myalgia/osteodynia (33.3% vs. 41.8%, p = 0.003), and dyspnea (14.0% vs. 25.3%, p < 0.001) were more likely to occur in non-rheumatic group after infection. Human immunoglobulin (2.1% vs. 0.2%, p = 0.006), glucocorticoids (19.5% vs. 1.6%, p < 0.001), oxygen support (6.8% vs. 2.1%, p < 0.001), and traditional Chinese medicine (21.9% vs. 16.6%, p = 0.037) were all more frequently used by rheumatic patients with COVID-19 infection. People in the control group were more confused about whether to use masks in following social activities after contracting COVID-19 (14.7% vs. 7.6%, p = 0.001). In the control group, more individuals than patients with rheumatic disease (25.1% vs. 13.4%, p < 0.001) expressed an interest to receive the vaccine again. After being exposed to COVID-19, the majority of rheumatic patients (66.9%) reported no discernible change, only 29.1% reported a worsening of their symptoms, and the remaining 4% indicated an improvement.CONCLUSIONSAfter the COVID-19 outbreak in China, the proportion of patients with rheumatic diseases infected with the virus was similar to that of normal individuals. But the clinical symptoms, follow-up treatment requirements, and awareness of the COVID-19 among rheumatic patients were distinct from those among non-rheumatic patients, necessitating the use of individualized diagnosis and treatment plans as well as health advice by medical professionals in clinical work. Key Points • Despite there were different comorbidities and vaccination rates, the rate of COVID-19 infection in patients with rheumatic disease was similar to that of normal individuals. • After COVID-19 infection, rheumatic patients and normal controls had different clinical symptoms and drug usage. • After being exposed to COVID-19, the majority of rheumatic patients felt no significant change in the primary disease, while the normal controls was more likely to accept a new vaccine injection and confused about whether to use masks in following social activities.

2010-03-01·Hinyokika kiyo. Acta urologica Japonica

[A case report of toxic shock syndrome after high orchiectomy].

Article

作者: Yoshikawa, Motokiyo ; Maruyama, Yoshio ; Matsumoto, Yoshihiro ; Yamada, Atsushi ; Yamamoto, Hiroaki ; Otani, Takeshi

We report our experience of toxic shock syndrome (TSS) in a 54-year-old male patient after high orchiectomy for testicular cancer. Four days after the surgery, he began to have diarrhea, high fever, and diffuse erythroderma followed by severe hypotension. There were no signs of postsurgical wound infection, so serious drug eruption was suspected. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the culture of the drain and result of skin biopsy, leading to the diagnosis of TSS. Following treatment with intravenous fluids, antibiotics, human immunoglobulin and corticosteroids, the symptoms went into remission. TSS progresses rapidly and becomes life-threatening if treatment is delayed. Therefore, when TSS is suspected in postsurgical patients who experience fever of 39 degrees C or higher, dermal erythema, shock, treatment should be started promptly.

2009-02-01·British Journal of Haematology2区 · 医学

Efficacy of a combination of human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes

2区 · 医学

Article

作者: Marilena Bertini ; Mario Boccadoro ; Roberto Sorasio ; Dario Ferrero ; Mariella Genuardi ; Antonella Darbesio ; Chiara Maria Dellacasa ; Valentina Giai

SummaryThe efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with ‘refractory anaemia’ according to the World Health Organization (WHO). We treated 63 MDS patients [excluding refractory anaemia with excess blasts, type 2 (RAEB2)] with a previously tested combination of 13‐cis‐retinoic acid and dihydroxylated vitamin D3 ± 6‐thioguanine in addition to rEPO. Most patients were categorized as refractory cytopenia with multilineage dysplasia and RAEB1, with intermediate 1 International Prognostic Scoring System (IPSS) score; all had Hb <95 g/l, and 70% required regular erythrocyte transfusions. Treatment was well tolerated, and erythroid response rate according to new International Working Group criteria was 60%: 50% in RAEB1 and 64% in non‐RAEB patients (P = 0·383). Response rate was not affected by transfusion requirement (63%; 58% in untransfused), IPSS and WHO Prognostic Scoring System scores, and weekly rEPO dosage (30–50 000 U vs. 80 000 U). Median response duration was 16 months. Median survival reached 14 months for RAEB1 and 55 months for non‐RAEB patients, with a significant difference in the latter between responders and non‐responders (median 82 months vs. 44 months; P = 0·036). Our combined therapy, independent of rEPO dosage, achieved in patients with unfavourable response predictors, a rate of anaemia improvement comparable to the best obtained in lower risk patients by high‐dose rEPO.

100 项与人免疫球蛋白(PH4)(国药集团上海血液制品有限公司) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAAAI2021	临床3期	原发性免疫缺陷疾病	27	Subcutaneous Human Immunoglobulin 16.5%	蓋鹽遞鹽鏇範糧糧簾築(鏇壓繭窪網簾觸夢積顧) = assessed as being related to the study drug 製遞夢餘鬱繭鑰築鹽範 (鏇鏇鹹窪壓膚淵繭憲衊 ) 更多	积极	2021-02-01